Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Total Liabilities
Everything the company owes to creditors and other parties.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 14.4% from a year ago
Total liabilities stood at $241.59M at the end of Q3 FY2026, up 14.4% from a year earlier and up 9.8% from the prior quarter. Over 3 fiscal years it compounded at +21.1% a year.
Context
- Total liabilities amounted to 54.5% of total assets at the end of Q3 FY2026, up 12.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +14.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 210.17M USD
- Year-over-year change
- -7.7%
- 4-year CAGR
- +46.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 210.17M | -7.7% |
| FY2024 | 2024-12-31 | 227.72M | +39.7% |
| FY2023 | 2023-12-31 | 162.99M | +37.9% |
| FY2022 | 2022-12-31 | 118.22M | +160.6% |
| FY2021 | 2021-12-31 | 45.37M | — |
Total Liabilities vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's Sep 2026 total liabilities of $241.59M is the 2nd highest of the 11 companies compared; the peer median is $49.34M.
- Its year-over-year change of +14.4% is the 7th highest of 11, against a peer median of +75.7%.
- Total liabilities amounts to 54.5% of total assets for RYTM, versus a peer median of 19.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.31T | +340892.5% | -5.3% | 45.9% | |
| Sep 2026 | $241.59M | +14.4% | +21.1% | 54.5% | |
SEPNSepterna, Inc. | Sep 2026 | $191.48M | -12.1% | +38.7% | 30.9% |
| Jun 2026 | $113.58M | +250.7% | +48.9% | 21.8% | |
| Mar 2026 | $78.01M | +91.3% | -4.6% | 18.6% | |
| Jun 2026 | $71.01M | +60.1% | -31.8% | 5.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $27.67M | +120.7% | -43.4% | 5.5% |
| Mar 2026 | $27.67M | +5.1% | +11.8% | 59.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M | -39.6% | -45.5% | 4.7% |
BLTEBelite Bio, Inc | Jun 2026 | $14.95M | +129.2% | +53.7% | 1.9% |
| Mar 2026 | $2.63M | -74.0% | -25.9% | 19.9% | |
| Peer median (excluding RYTM) | $49.34M | +75.7% | -4.9% | 19.2% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.25M | 127.68M | 60.08M | 89.14M | 54.3M |
| Short-term Investments | 235.61M | 205.61M | 215.77M | 231.43M | 334.65M |
| Net Receivables | 1.03M | 6.22M | 14.87M | 18.51M | 26.08M |
| Inventory | 111K | 2.92M | 8.62M | 18.74M | 25.75M |
| Other Current Assets | 3.99M | 7.42M | 6.67M | 8.8M | 9.97M |
| Total Current Assets | 308.39M | 354.24M | 308.27M | 374.2M | 466.92M |
| Property, Plant & Equipment (Net) | 4.34M | 3.38M | 2.12M | 4.11M | 4.15M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.66M | 7.88M | 7.03M | 6.17M | 5.32M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.14M | 16.98M | 15.33M | 7.79M | 3.81M |
| Total Non-current Assets | 21.14M | 28.25M | 24.48M | 18.07M | 13.28M |
| Total Assets | 329.52M | 382.48M | 332.75M | 392.27M | 480.2M |
| Account Payables | 5.74M | 4.8M | 4.89M | 12.33M | 13.95M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7M | 1.43M | 1.29M | 1.29M | 194K |
| Other Current Liabilities | 800K | 2.42M | 5.41M | 43.6M | 11.37M |
| Total Current Liabilities | 43.43M | 39.81M | 55.2M | 115.52M | 105.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 77.15M | 107.29M | 108.27M | 100.89M |
| Total Non-current Liabilities | 1.95M | 78.41M | 107.78M | 112.21M | 104.23M |
| Total Liabilities | 45.37M | 118.22M | 162.99M | 227.72M | 210.17M |
| Common Stock | 50K | 56K | 59K | 61K | 67K |
| Retained Earnings | (528.94M) | (710.06M) | (894.74M) | (1.16B) | (1.35B) |
| Accumulated OCI | (1K) | (92K) | 134K | (39K) | (796K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.15M | 264.26M | 169.76M | 164.55M | 270.03M |
| Total Debt | 2.55M | 1.94M | 1.26M | 3.94M | 3.99M |
| Net Debt | (56.7M) | (125.73M) | (58.82M) | (85.2M) | (50.31M) |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.